Dr. Reddy's Defeat Of FCA Case Offers 'Guidepost' For Litigation After Escobar
Executive Summary
Dismissal of False Claims Act suit against Dr. Reddy's shows impact of US Supreme Court's Escobar decision. Government FCA pharma recoveries shot up 58% from 2015 to 2016; graphic breaks out settlements by kickback, off-label promotion and improper billing cases.
You may also be interested in...
Pharma Deals With The DOJ
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
Off-label marketing and kickbacks may no longer be the top targets of government healthcare fraud investigations as more companies are being hit with subpoenas for pricing information.
Pfizer Protonix Settlement May Deter Price Bundling
$784.6m fine will resolve claims that Wyeth subsidiary paid hospitals steep discounts if they purchased both oral and IV Protonix while reporting higher prices to the government.